Eli Lilly’s Dan Skovronsky on oral GLP-1, ‘slower ramp’ for Alzheimer’s and deals on ‘underappreciated’ assets

Dan Skovron­sky knows that any con­ver­sa­tion about Eli Lil­ly is go­ing to be large­ly about its work in obe­si­ty and Alzheimer’s. Al­though he wants every­one to know that the com­pa­ny is al­so ex­cit­ed about can­di­dates in im­munol­o­gy and on­col­o­gy, he’s al­so ready to take ques­tions about those hottest top­ics head-on.

Speak­ing at an in­vestor con­fer­ence or­ga­nized by Ever­core ISI, Skovron­sky — whose string of ti­tles at Lil­ly in­cludes ex­ec­u­tive vice pres­i­dent, chief sci­en­tif­ic and med­ical of­fi­cer, and pres­i­dent of Lil­ly Re­search Lab­o­ra­to­ries — ad­dressed both high-lev­el and gran­u­lar ques­tions about the pipeline and strat­e­gy.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.